Risankizumab versus ustekinumab for Crohn’s disease: a phase IIIb study

IF 45.9 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Nature Reviews Gastroenterology &Hepatology Pub Date : 2024-08-05 DOI:10.1038/s41575-024-00973-6

Eleni Kotsiliti

引用次数: 0

查看原文本刊更多论文

利桑珠单抗与乌司他单抗治疗克罗恩病：IIIb 期研究

发表在《新英格兰医学杂志》上的一项多中心、开放标签、对照 IIIb 期临床试验（SEQUENCE）比较了利桑珠单抗（一种靶向 IL-23A 的单克隆抗体）和乌斯特库单抗（一种靶向 IL-12 和 IL-23 的单克隆抗体）对曾接受抗肿瘤坏死因子治疗无效或出现不可接受的不良反应的中重度克罗恩病患者的疗效和安全性。患者（n = 520）被随机分配接受利桑单抗（n = 255）或乌斯特库单抗（n = 265；72.8%的患者完成了所有分配的治疗）。两个主要终点均已达到，即第24周时的临床缓解和第48周时的内镜缓解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Gastroenterology &Hepatology 医学-胃肠肝病学

CiteScore

52.30

自引率

0.60%

发文量

147

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication. The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information. Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.